Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
PEN Penumbra
250.410+0.410+0.16%
Close
01/31 16:00 ET
250.4100.0000.00%
Post Mkt Price 01/31 16:26 ET
High
252.490
Open
250.000
Turnover
87.87M
Low
245.890
Pre Close
250.000
Volume
352.85K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Penumbra Price Target Raised to $284 From $255 at Truist
Penumbra (NYSE:PEN) Receives New Coverage From Analysts at Piper Sandler
Piper Sandler started coverage on shares of Penumbra (NYSE:PEN – Get Rating) in a research note published on Monday morning, The Fly reports. The firm issued an overweight rating and a $275.00 target
BTIG Adjusts Price Target on Penumbra to $270 From $240, Maintains Buy Rating
08:45 AM EST, 01/30/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Penumbra Is Maintained at Buy by BTIG
Penumbra Price Target Raised to $270.00/Share From $240.00 by BTIG
BTIG Maintains Buy on Penumbra, Raises Price Target to $270
BTIG analyst Ryan Zimmerman maintains Penumbra (NYSE:PEN) with a Buy and raises the price target from $240 to $270.
Penumbra Price Target Raised to $270 From $240 at BTIG
Penumbra Price Target Announced at $275.00/Share by Piper Sandler
Penumbra Initiated at Overweight by Piper Sandler
Piper Sandler Initiates Coverage On Penumbra With Overweight Rating, Announces Price Target of $275
Piper Sandler analyst Matt O'Brien initiates coverage on Penumbra (NYSE:PEN) with a Overweight rating and announces Price Target of $275.
Company Overview
More
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. Its target markets include interventional neuroradiologists, neurosurgeons, neurologists, cardiologists, radiologists, and vascular surgeons. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.
CEO： Mr. Adam Elsesser
Market： NYSE
Listing Date： 09/18/2015
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet